Literature DB >> 8460938

Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of catalytic activities.

S Bhamre1, H K Anandatheerathavarada, S K Shankar, M R Boyd, V Ravindranath.   

Abstract

The present study demonstrates the presence of multiple forms of cytochrome P450 (P450) in human brain obtained at autopsy, the purification of various isoforms to apparent homogeneity, and the monooxygenase activities in reconstituted systems. Sequential chromatography on octylamino-Sepharose 4B, DEAE-Sephacel, and DEAE-cellulose yielded four isoforms of P450 (A, B, C, and D) with specific contents of 11.0, 9.4, 12.5, and 8.3 nmol of P450/mg protein, respectively. While the forms A, B, and C were apparently homogeneous as examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis; the P450D was not homogeneous. The apparent molecular masses of the four forms of P450 were 60,200 Da (P450A), 60,900 Da (P450B), 60,200 Da (P450C), and 61,000 Da (P450D), respectively. NADPH cytochrome P450 reductase (reductase) was also partially purified from the brain microsomes. Immunoblot analysis of the four forms of human purified P450, using antisera to purified rat liver P450 (IIB1 + IIB2), rat liver P450 (1A1 + 1A2), phenobarbital-inducible rat brain P450, human liver P450 IIE1, P450 1A2, P450 IIC, and P450 IIIA4, indicated differential immunological cross-reactivity. The monooxygenase activities of the purified human brain P450s were demonstrated with various substrates (aminopyrine, morphine, aniline, 7-ethoxycoumarin, and nifedipine) as examined in reconstituted systems consisting of purified human brain P450, purified rat brain NADPH cytochrome P450 reductase, deoxycholate, phospholipid, and NADPH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8460938     DOI: 10.1006/abbi.1993.1141

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

Review 2.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 3.  Cytochrome P450-mediated drug metabolism in the brain.

Authors:  Sharon Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2013-05       Impact factor: 6.186

4.  Cyp7b, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7alpha-hydroxy dehydroepiandrosterone and 7alpha-hydroxy pregnenolone.

Authors:  K A Rose; G Stapleton; K Dott; M P Kieny; R Best; M Schwarz; D W Russell; I Björkhem; J Seckl; R Lathe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

Review 5.  Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy.

Authors:  Megha Gautam; Ganesh Thapa
Journal:  Acta Neurol Belg       Date:  2020-08-02       Impact factor: 2.396

Review 6.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.